X

Drug Profile

Research programme: hypercholesterolaemia therapies - Incyte

Alternative Names: MX 6046; MX 7291

Latest Information Update: 19 Sep 2006

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Incyte Corporation
Class
Mechanism of Action Cholesterol absorption inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Hypercholesterolaemia

Most Recent Events

19 Sep 2006 Discontinued - Preclinical for Hypercholesterolaemia in USA (unspecified route)
30 Apr 2003 Incyte Genomics is now called Incyte Corporation
03 Mar 2003 Maxia Pharmaceuticals has been acquired by Incyte Genomics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com